top of page
NANO₂

NanO₂ was designed to increase oxygen delivery in the body, aiming to reverse tissue hypoxia.

Nan02.png

Hypoxia happens when the body’s cells cannot get enough oxygen, and it plays a critical role in the progression of many diseases even causing death.​ Our goal is to reverse tissue hypoxia, the root cause for death, injury, and resistance in treatment in these diseases.

nano2-step-1.png

After IV infusion, NanO₂ forms nanodroplets inside the body.

nano2-step-2.png

These droplets pick up oxygen from the lungs and deliver it to the cells that need it.

nano2-step-3.png

The active pharmaceutical ingredient (API) of NanO₂ is then exhaled and not metabolized.

Clinical Studies

NuvOx Therapeutics is conducting clinical trials in Glioblastoma, Stroke, and Respiratory Distress to evaluate the safety and efficacy of NanO₂. Please click the links below to learn more.

NanO₂ is under clinical investigation and not yet approved for general medical use.

COMPLETED

Glioblastoma Phase Ib/IIa

Stroke Phase Ib/IIa

RECRUITING

Glioblastoma Phase IIb

The RESTORE Study is recruiting in the United States for patients with newly diagnosed Glioblastoma.

We would love to hear from you.

We are here to assist. A representative from NuvOx will follow up shortly.

bottom of page